Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
暂无分享,去创建一个
H. Feldman | R. Tanzi | Doo Yeon Kim | W. Gerwick | Yadong Huang | J. Momper | L. Quinti | A. Griciuc | Sonia Podvin | Ben Boyarko | Anne Bang | V. Hook | Barry Greenberg
[1] Yingwei Wang,et al. Spatiotemporal expression patterns of genes coding for plasmalemmal chloride transporters and channels in neurological diseases , 2023, Molecular Brain.
[2] M. Gorospe,et al. Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease , 2022, Molecular Psychiatry.
[3] Mari A. Virtanen,et al. Expression patterns of NKCC1 in neurons and non-neuronal cells during cortico-hippocampal development , 2022, Cerebral cortex.
[4] R. Bateman,et al. Lecanemab in Early Alzheimer's Disease. , 2022, The New England journal of medicine.
[5] William T. Ralvenius,et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes , 2022, Nature.
[6] A. Saykin,et al. Myelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics , 2022, Translational Neurodegeneration.
[7] McKenzie Prillaman. Alzheimer’s drug slows mental decline in trial — but is it a breakthrough? , 2022, Nature.
[8] A. Koyama,et al. Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease , 2022, CPT: pharmacometrics & systems pharmacology.
[9] R. Rissman,et al. Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer’s Disease Brain , 2022, ACS chemical neuroscience.
[10] L. Schneider,et al. Making the Case for Accelerated Withdrawal of Aducanumab. , 2022, Journal of Alzheimer's disease : JAD.
[11] R. Faull,et al. Beta-Amyloid (Aβ1-42) Increases the Expression of NKCC1 in the Mouse Hippocampus , 2022, Molecules.
[12] F. Barkhof,et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease , 2022, The Journal of Prevention of Alzheimer's Disease.
[13] A. Alia,et al. Evaluation of suprachiasmatic nucleus in Alzheimer’s disease with non-invasive magnetic resonance methods , 2022, Neural regeneration research.
[14] K. Kaila,et al. The NKCC1 ion transporter modulates microglial phenotype and inflammatory response to brain injury in a cell-autonomous manner , 2022, PLoS biology.
[15] Mina Esmail Zadeh Nojoo Kambar,et al. Alzheimer's disease drug development pipeline: 2022 , 2022, Alzheimer's & dementia.
[16] K. Kaila,et al. CNS pharmacology of NKCC1 inhibitors , 2021, Neuropharmacology.
[17] A. Sporbert,et al. Microglia sense neuronal activity via GABA in the early postnatal hippocampus. , 2021, Cell reports.
[18] Gui-hong Zhang,et al. Microglia in Alzheimer’s Disease: A Target for Therapeutic Intervention , 2021, Frontiers in Cellular Neuroscience.
[19] P. Scheltens,et al. The Alzheimer’s disease drug development landscape , 2021, Alzheimer's Research & Therapy.
[20] M. De Vivo,et al. Pharmacological tools to target NKCC1 in brain disorders. , 2021, Trends in pharmacological sciences.
[21] Fayzan F. Chaudhry,et al. Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease , 2021, Nature Aging.
[22] P. Tariot,et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease , 2021, Nature Reviews Neurology.
[23] A. Atri,et al. Aducanumab: Appropriate Use Recommendations , 2021, The Journal of Prevention of Alzheimer's Disease.
[24] W. Löscher,et al. A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia , 2021, Epilepsia.
[25] L. Ferrucci,et al. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease , 2021, Ageing Research Reviews.
[26] M. Mintun,et al. Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.
[27] M. Kivimäki,et al. The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study , 2021, Alzheimer's research & therapy.
[28] B. Hyman,et al. APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. , 2021, The Lancet Neurology.
[29] G. Perea,et al. GABAergic signaling to astrocytes in the prefrontal cortex sustains goal-directed behaviors , 2020, Nature Neuroscience.
[30] W. Löscher,et al. The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain , 2020, Epilepsy & Behavior.
[31] Mari A. Virtanen,et al. NKCC1, an Elusive Molecular Target in Brain Development: Making Sense of the Existing Data , 2020, Cells.
[32] W. Löscher,et al. Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective , 2020, Epilepsia.
[33] Shanshan Song,et al. Ion channels and transporters in microglial function in physiology and brain diseases , 2020, Neurochemistry International.
[34] W. Löscher,et al. Hydrolytic biotransformation of the bumetanide ester prodrug DIMAEB to bumetanide by esterases in neonatal human and rat serum and neonatal rat brain—A new treatment strategy for neonatal seizures? , 2020, Epilepsia.
[35] S. R. Datta,et al. GABA-receptive microglia selectively sculpt developing inhibitory circuits , 2020, Cell.
[36] Punam Sawant-Pokam,et al. Preventing neuronal edema increases network excitability after traumatic brain injury. , 2020, The Journal of clinical investigation.
[37] N. Zuithoff,et al. Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase Two, Superiority Trial. , 2020, Journal of the American Academy of Child and Adolescent Psychiatry.
[38] R. Bertorelli,et al. Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders , 2020, Chem.
[39] M. Theus,et al. Mechanisms of Blood–Brain Barrier Dysfunction in Traumatic Brain Injury , 2020, International journal of molecular sciences.
[40] O. Forlenza,et al. Passive antiamyloid immunotherapy for Alzheimer's disease. , 2020, Current opinion in psychiatry.
[41] T. Al‐Tel,et al. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease , 2020, Medicinal research reviews.
[42] G. Bu,et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies , 2019, Nature Reviews Neurology.
[43] S. Kadam,et al. Off-Label Use of Bumetanide for Brain Disorders: An Overview , 2019, Front. Neurosci..
[44] B. Molyneaux,et al. A Novel Na+-K+-Cl− Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke , 2019, Stroke.
[45] D. Michaelson,et al. ApoE4: an emerging therapeutic target for Alzheimer’s disease , 2019, BMC Medicine.
[46] M. Bozzali,et al. Ventral tegmental area disruption in Alzheimer’s disease , 2019, Aging.
[47] O. Fiehn,et al. Metabolomics Analyses of 14 Classical Neurotransmitters by GC-TOF with LC-MS Illustrates Secretion of 9 Cell-Cell Signaling Molecules from Sympathoadrenal Chromaffin Cells in the Presence of Lithium. , 2019, ACS chemical neuroscience.
[48] F. Colbourne,et al. Failure of bumetanide to improve outcome after intracerebral hemorrhage in rat , 2019, PloS one.
[49] W. Löscher,et al. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy , 2018, Neuropharmacology.
[50] Jason H. Huang,et al. Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets , 2018, Journal of neuroscience research.
[51] E. Sigurdsson,et al. Tau-targeting therapies for Alzheimer disease , 2018, Nature Reviews Neurology.
[52] K. Lenz,et al. Microglia and Beyond: Innate Immune Cells As Regulators of Brain Development and Behavioral Function , 2018, Front. Immunol..
[53] M. Xie,et al. NKCC1 Inhibition Attenuates Chronic Cerebral Hypoperfusion-Induced White Matter Lesions by Enhancing Progenitor Cells of Oligodendrocyte Proliferation , 2018, Journal of Molecular Neuroscience.
[54] Nicole R. Zürcher,et al. Bumetanide for autism: more eye contact, less amygdala activation , 2018, Scientific Reports.
[55] M. Joghataei,et al. Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial , 2017, Schizophrenia Research.
[56] Jun Chen,et al. Inhibition of Na+-K+-2Cl− cotransporter attenuates blood-brain-barrier disruption in a mouse model of traumatic brain injury , 2017, Neurochemistry International.
[57] W. Löscher,et al. Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain , 2017, Neuropharmacology.
[58] Kai Gu,et al. Gamma secretase inhibitors: a patent review (2013 - 2015) , 2017, Expert opinion on therapeutic patents.
[59] I. Dewachter,et al. Cortical cells reveal APP as a new player in the regulation of GABAergic neurotransmission , 2017, Scientific Reports.
[60] Y. Ben-Ari,et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders , 2017, Translational Psychiatry.
[61] M. Joghataei,et al. Lack of the effect of bumetanide, a selective NKCC1 inhibitor, in patients with schizophrenia: A double‐blind randomized trial , 2017, Psychiatry and clinical neurosciences.
[62] G. Alves,et al. Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review. , 2016, Current Alzheimer research.
[63] N. Jovanov-Milošević,et al. Developmental Expression Patterns of KCC2 and Functionally Associated Molecules in the Human Brain. , 2016, Cerebral cortex.
[64] D. Holtzman,et al. Mechanisms linking circadian clocks, sleep, and neurodegeneration , 2016, Science.
[65] M. Sur,et al. Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome , 2016, Proceedings of the National Academy of Sciences.
[66] R. Salvi,et al. Ototoxic effects and mechanisms of loop diuretics , 2016, Journal of otology.
[67] M. Nedergaard,et al. NKCC1 up-regulation contributes to early post-traumatic seizures and increased post-traumatic seizure susceptibility , 2016, Brain Structure and Function.
[68] M. Bozzali,et al. Quantitative MRI to understand Alzheimer's disease pathophysiology. , 2016, Current opinion in neurology.
[69] W. Löscher,et al. The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice , 2016, Epilepsia.
[70] Z. Fei,et al. Inhibition of Na+-K+-2Cl- Cotransporter-1 attenuates traumatic brain injury-induced neuronal apoptosis via regulation of Erk signaling , 2016, Neurochemistry International.
[71] A. Pérez-Samartín,et al. Axon-to-Glia Interaction Regulates GABAA Receptor Expression in Oligodendrocytes , 2016, Molecular Pharmacology.
[72] N. Bandeira,et al. Neuropeptidomics Mass Spectrometry Reveals Signaling Networks Generated by Distinct Protease Pathways in Human Systems , 2015, Journal of The American Society for Mass Spectrometry.
[73] B. Wang,et al. A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism. , 2015, Journal of child and adolescent psychopharmacology.
[74] M. Chonchol,et al. Renal control of calcium, phosphate, and magnesium homeostasis. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[75] B. Griffin,et al. The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat , 2015, The Journal of pharmacy and pharmacology.
[76] C. Zhao,et al. In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures , 2015, Neuroscience.
[77] W. Löscher,et al. The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. , 2015, European journal of pharmacology.
[78] D. Mount. Thick ascending limb of the loop of Henle. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[79] Basavaraj Hooli,et al. A three-dimensional human neural cell culture model of Alzheimer’s disease , 2014, Nature.
[80] J. A. Payne,et al. Cation-chloride cotransporters in neuronal development, plasticity and disease , 2014, Nature Reviews Neuroscience.
[81] K. Kaila,et al. Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures , 2014, Epilepsia.
[82] W. Löscher,et al. A novel prodrug‐based strategy to increase effects of bumetanide in epilepsy , 2014, Annals of neurology.
[83] Amene Shahrokhi,et al. Oxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring , 2014, Science.
[84] W. Löscher,et al. Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy , 2014, The European journal of neuroscience.
[85] 조현철,et al. Intracerebral Hemorrhage(ICH) 수술 유도 로봇 시스템을 위한 수술 유도 도구 켈리브레이션 , 2014 .
[86] F. Jensen,et al. Bumetanide Enhances Phenobarbital Efficacy in a Rat Model of Hypoxic Neonatal Seizures , 2013, PloS one.
[87] Huaxi Xu,et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.
[88] M. Hadjighassem,et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy , 2013, Epilepsia.
[89] Y. Ben-Ari,et al. A randomised controlled trial of bumetanide in the treatment of autism in children , 2012, Translational Psychiatry.
[90] Lydia Ng,et al. Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system , 2012, Nucleic Acids Res..
[91] Junsung Woo,et al. Astrocytes as GABA-ergic and GABA-ceptive Cells , 2012, Neurochemical Research.
[92] E. Castrén,et al. The Loop Diuretic Bumetanide Blocks Posttraumatic p75NTR Upregulation and Rescues Injured Neurons , 2012, The Journal of Neuroscience.
[93] H. Arrighi,et al. Prevalence of Apolipoprotein E4 Genotype and Homozygotes (APOE e4/4) among Patients Diagnosed with Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.
[94] M. Sabbagh,et al. New Acetylcholinesterase Inhibitors for Alzheimer's Disease , 2011, International journal of Alzheimer's disease.
[95] P. Ortiz,et al. Molecular regulation of NKCC2 in the thick ascending limb. , 2011, American journal of physiology. Renal physiology.
[96] J. Soul,et al. Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[97] Y. Ben-Ari,et al. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects , 2010, Acta paediatrica.
[98] J. Simard,et al. Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4. , 2010, Journal of neurosurgery.
[99] O. Witte,et al. Downregulation of Potassium Chloride Cotransporter KCC2 After Transient Focal Cerebral Ischemia , 2010, Stroke.
[100] K. Staley,et al. Decreased Seizure Activity in a Human Neonate Treated With Bumetanide, an Inhibitor of the Na+-K+-2Cl- Cotransporter NKCC1 , 2009, Journal of child neurology.
[101] M. Norenberg,et al. Na-K-Cl Cotransporter-1 in the Mechanism of Ammonia-induced Astrocyte Swelling* , 2008, Journal of Biological Chemistry.
[102] G. Buzsáki,et al. Inhibition and Brain Work , 2007, Neuron.
[103] R. Miles,et al. Perturbed Chloride Homeostasis and GABAergic Signaling in Human Temporal Lobe Epilepsy , 2007, The Journal of Neuroscience.
[104] D. Kintner,et al. AMPA‐mediated excitotoxicity in oligodendrocytes: role for Na+–K+–Cl− co‐transport and reversal of Na+/Ca2+ exchanger , 2007, Journal of neurochemistry.
[105] K. Lu,et al. Bumetanide administration attenuated traumatic brain injury through IL-1 overexpression , 2007, Neurological research.
[106] K. Lu,et al. Inhibition of the Na+ -K+ -2Cl- -cotransporter in choroid plexus attenuates traumatic brain injury-induced brain edema and neuronal damage. , 2006, European journal of pharmacology.
[107] J. Birks,et al. Cholinesterase inhibitors for Alzheimer's disease. , 2006 .
[108] M. O’Donnell,et al. Moderate-to-severe ischemic conditions increase activity and phosphorylation of the cerebral microvascular endothelial cell Na+-K+-Cl- cotransporter. , 2005, American journal of physiology. Cell physiology.
[109] D. Kintner,et al. Na-K-Cl Cotransporter-Mediated Intracellular Na+ Accumulation Affects Ca2+ Signaling in Astrocytes in an In Vitro Ischemic Model , 2004, The Journal of Neuroscience.
[110] Lien Tran,et al. Bumetanide Inhibition of the Blood-Brain Barrier Na-K-Cl Cotransporter Reduces Edema Formation in the Rat Middle Cerebral Artery Occlusion Model of Stroke , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[111] P. Barthó,et al. Differential distribution of the KCl cotransporter KCC2 in thalamic relay and reticular nuclei , 2004, The European journal of neuroscience.
[112] J. Tepper,et al. Cell Type-Specific Differences in Chloride-Regulatory Mechanisms and GABAA Receptor-Mediated Inhibition in Rat Substantia Nigra , 2003, The Journal of Neuroscience.
[113] Hao Wang,et al. GABA-mediated trophic effect on oligodendrocytes requires Na-K-2Cl cotransport activity. , 2003, Journal of neurophysiology.
[114] Juha Voipio,et al. Cation–chloride co-transporters in neuronal communication, development and trauma , 2003, Trends in Neurosciences.
[115] J. Voipio,et al. BDNF-induced TrkB activation down-regulates the K+–Cl− cotransporter KCC2 and impairs neuronal Cl− extrusion , 2002, The Journal of cell biology.
[116] Y. Ben-Ari. Excitatory actions of gaba during development: the nature of the nurture , 2002, Nature Reviews Neuroscience.
[117] D. Kintner,et al. Astrocytes from Na(+)-K(+)-Cl(-) cotransporter-null mice exhibit absence of swelling and decrease in EAA release. , 2002, American journal of physiology. Cell physiology.
[118] W. Hauser,et al. Are certain diuretics also anticonvulsants? , 2001, Annals of neurology.
[119] J. A. Payne,et al. The Neuron-specific K-Cl Cotransporter, KCC2 , 1999, The Journal of Biological Chemistry.
[120] J. A. Payne,et al. The K+/Cl− co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation , 1999, Nature.
[121] J. Mellor,et al. Properties of GABAA receptors in cultured rat oligodendrocyte progenitor cells , 1998, Neuropharmacology.
[122] S. Hebert,et al. Ionic conductance pathways in the mouse medullary thick ascending limb of Henle. The paracellular pathway and electrogenic Cl- absorption , 1986, The Journal of general physiology.
[123] W. Colburn,et al. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. , 1984, Journal of pharmaceutical sciences.
[124] R. D. Brown. Effect of bumetanide on the positive endocochlear dc potential of the cat. , 1976, Toxicology and applied pharmacology.
[125] R. Vergona,et al. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog. , 1976, The Journal of pharmacology and experimental therapeutics.
[126] M. Burg. Tubular chloride transport and the mode of action of some diuretics. , 1976, Kidney international.
[127] A. J. Duvall,et al. Early changes in the cochlear duct from ethacrynic ACID: An electronmicroscopic evaluation , 1970, The Laryngoscope.
[128] K. Blennow,et al. Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force , 2019, The Journal of Prevention of Alzheimer's Disease.
[129] C. Schwarzer,et al. Functional characterization of novel bumetanide derivatives for epilepsy treatment , 2019, Neuropharmacology.
[130] J. Meijer,et al. Degeneration of the Suprachiasmatic Nucleus in an Alzheimer's Disease Mouse Model Monitored by in vivo Magnetic Resonance Relaxation Measurements and Immunohistochemistry. , 2019, Journal of Alzheimer's disease : JAD.
[131] Ghulam Md Ashraf,et al. Cholinesterase Inhibitors for Alzheimer Disease: Multitargeting Strategy based on Anti-Alzheimer's Drugs Repositioning. , 2019, Current pharmaceutical design.
[132] R. Klein,et al. Prevalence of ototoxic medication use among older adults in Beaver Dam, Wisconsin , 2018, Journal of the American Association of Nurse Practitioners.
[133] T. Ikuta,et al. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. , 2017, Journal of Alzheimer's disease : JAD.
[134] P. Damier,et al. Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. , 2016, Clinical neuropharmacology.
[135] R. Tanzi,et al. Recapitulating amyloid β and tau pathology in human neural cell culture models: clinical implications. , 2015, US neurology.
[136] D. Price,et al. Basic neurochemistry : principles of molecular, cellular and medical neurobiology , 2012 .
[137] D. M. Robinson,et al. Memantine: a review of its use in Alzheimer's disease. , 2006, Drugs.
[138] Wen‐Hui Wang. Regulation of ROMK (Kir1.1) channels: new mechanisms and aspects. , 2006, American journal of physiology. Renal physiology.
[139] P. A. Friedman,et al. Effects of antidiuretic hormone on cellular conductive pathways in mouse medullary thick ascending limbs of Henle: I. ADH increases transcellular conductance pathways , 2005, The Journal of Membrane Biology.
[140] G. Giebisch. Diuretic action of potassium channel blockers , 2005, European Journal of Clinical Pharmacology.
[141] S. Hebert,et al. Effects of antidiuretic hormone on cellular conductive pathways in mouse medullary thick ascending limbs of Henle: II. Determinants of the ADH-mediated increases in transepithelial voltage and in net Cl− absorption , 2005, The Journal of Membrane Biology.
[142] J. Russell. Sodium-potassium-chloride cotransport. , 2000, Physiological reviews.